CN104083428B - 治疗风湿、腰椎间盘突出的药物及其方法 - Google Patents
治疗风湿、腰椎间盘突出的药物及其方法 Download PDFInfo
- Publication number
- CN104083428B CN104083428B CN201410246427.XA CN201410246427A CN104083428B CN 104083428 B CN104083428 B CN 104083428B CN 201410246427 A CN201410246427 A CN 201410246427A CN 104083428 B CN104083428 B CN 104083428B
- Authority
- CN
- China
- Prior art keywords
- parts
- root
- medicine
- treatment
- protrusion
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000003814 drug Substances 0.000 title claims abstract description 33
- 238000000034 method Methods 0.000 title claims abstract description 9
- 235000014101 wine Nutrition 0.000 claims abstract description 21
- 241001148782 Davallia Species 0.000 claims abstract description 9
- 241001251068 Formica fusca Species 0.000 claims abstract description 9
- 241000195947 Lycopodium Species 0.000 claims abstract description 9
- 241001521394 Maackia amurensis Species 0.000 claims abstract description 9
- 241000361919 Metaphire sieboldi Species 0.000 claims abstract description 9
- 241000132171 Phryma leptostachya Species 0.000 claims abstract description 9
- 239000002689 soil Substances 0.000 claims abstract description 9
- 240000008042 Zea mays Species 0.000 claims abstract description 8
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 claims abstract description 8
- 235000002017 Zea mays subsp mays Nutrition 0.000 claims abstract description 8
- 235000005822 corn Nutrition 0.000 claims abstract description 8
- 239000002994 raw material Substances 0.000 claims abstract description 6
- 244000017020 Ipomoea batatas Species 0.000 claims abstract 2
- 235000002678 Ipomoea batatas Nutrition 0.000 claims abstract 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 12
- 241000580923 Acer buergerianum Species 0.000 claims description 4
- 241000242759 Actiniaria Species 0.000 claims description 4
- 241000205585 Aquilegia canadensis Species 0.000 claims description 4
- 235000007650 Aralia spinosa Nutrition 0.000 claims description 4
- 241001568514 Ardisia gigantifolia Species 0.000 claims description 4
- 241000345998 Calamus manan Species 0.000 claims description 4
- 241000723346 Cinnamomum camphora Species 0.000 claims description 4
- 240000006927 Foeniculum vulgare Species 0.000 claims description 4
- 235000004204 Foeniculum vulgare Nutrition 0.000 claims description 4
- 241001456094 Laportea canadensis Species 0.000 claims description 4
- 241000112528 Ligusticum striatum Species 0.000 claims description 4
- 241000219991 Lythraceae Species 0.000 claims description 4
- 244000153955 Reynoutria sachalinensis Species 0.000 claims description 4
- 235000003202 Reynoutria sachalinensis Nutrition 0.000 claims description 4
- 102000011842 Serrate-Jagged Proteins Human genes 0.000 claims description 4
- 108010036039 Serrate-Jagged Proteins Proteins 0.000 claims description 4
- 244000290970 Tetrapanax papyrifer Species 0.000 claims description 4
- 241000949456 Zanthoxylum Species 0.000 claims description 4
- 210000003127 knee Anatomy 0.000 claims description 4
- 235000012950 rattan cane Nutrition 0.000 claims description 4
- 239000011435 rock Substances 0.000 claims description 4
- 235000009754 Vitis X bourquina Nutrition 0.000 claims description 3
- 235000012333 Vitis X labruscana Nutrition 0.000 claims description 3
- 240000006365 Vitis vinifera Species 0.000 claims description 3
- 235000014787 Vitis vinifera Nutrition 0.000 claims description 3
- 241000601164 Clematis orientalis Species 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 238000007789 sealing Methods 0.000 claims description 2
- 241000721153 Chloranthus japonicus Species 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 22
- 208000002193 Pain Diseases 0.000 abstract description 9
- 229940079593 drug Drugs 0.000 abstract description 9
- 230000036407 pain Effects 0.000 abstract description 9
- 238000003745 diagnosis Methods 0.000 abstract description 8
- 210000004369 blood Anatomy 0.000 abstract description 6
- 239000008280 blood Substances 0.000 abstract description 6
- 238000012795 verification Methods 0.000 abstract description 4
- 230000003213 activating effect Effects 0.000 abstract description 3
- 230000001737 promoting effect Effects 0.000 abstract description 3
- 230000008961 swelling Effects 0.000 abstract description 3
- 230000017531 blood circulation Effects 0.000 abstract description 2
- 231100000419 toxicity Toxicity 0.000 abstract description 2
- 230000001988 toxicity Effects 0.000 abstract description 2
- 239000007788 liquid Substances 0.000 description 13
- 201000010099 disease Diseases 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 235000017965 Asarum canadense Nutrition 0.000 description 7
- 235000000385 Costus speciosus Nutrition 0.000 description 7
- 241000606265 Valeriana jatamansi Species 0.000 description 7
- 235000014687 Zingiber zerumbet Nutrition 0.000 description 7
- 210000003141 lower extremity Anatomy 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- 206010019468 Hemiplegia Diseases 0.000 description 5
- 230000002490 cerebral effect Effects 0.000 description 5
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 241000721167 Chloranthus Species 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 208000025747 Rheumatic disease Diseases 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000002349 favourable effect Effects 0.000 description 3
- 208000034783 hypoesthesia Diseases 0.000 description 3
- 230000001976 improved effect Effects 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 210000005036 nerve Anatomy 0.000 description 3
- 238000004393 prognosis Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 206010019233 Headaches Diseases 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 201000001429 Intracranial Thrombosis Diseases 0.000 description 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
- 206010067482 No adverse event Diseases 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- 206010046996 Varicose vein Diseases 0.000 description 2
- 238000001467 acupuncture Methods 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000003356 anti-rheumatic effect Effects 0.000 description 2
- 239000003435 antirheumatic agent Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000005786 degenerative changes Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 229960000485 methotrexate Drugs 0.000 description 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- 231100000862 numbness Toxicity 0.000 description 2
- 201000003068 rheumatic fever Diseases 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 208000027185 varicose disease Diseases 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- LJRDOKAZOAKLDU-UDXJMMFXSA-N (2s,3s,4r,5r,6r)-5-amino-2-(aminomethyl)-6-[(2r,3s,4r,5s)-5-[(1r,2r,3s,5r,6s)-3,5-diamino-2-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-hydroxycyclohexyl]oxy-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxyoxane-3,4-diol;sulfuric ac Chemical compound OS(O)(=O)=O.N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO LJRDOKAZOAKLDU-UDXJMMFXSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 241000219106 Bryonia Species 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 206010008088 Cerebral artery embolism Diseases 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 229930105110 Cyclosporin A Natural products 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 101100136092 Drosophila melanogaster peng gene Proteins 0.000 description 1
- 208000002513 Flank pain Diseases 0.000 description 1
- 208000004044 Hypesthesia Diseases 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 208000003618 Intervertebral Disc Displacement Diseases 0.000 description 1
- 208000018650 Intervertebral disc disease Diseases 0.000 description 1
- 208000032984 Intraoperative Complications Diseases 0.000 description 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229960003677 chloroquine Drugs 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
- 229960001259 diclofenac Drugs 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 210000002310 elbow joint Anatomy 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 210000002391 femur head Anatomy 0.000 description 1
- 210000003811 finger Anatomy 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 210000005224 forefinger Anatomy 0.000 description 1
- 238000005755 formation reaction Methods 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 229940076085 gold Drugs 0.000 description 1
- 210000002149 gonad Anatomy 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- XXSMGPRMXLTPCZ-UHFFFAOYSA-N hydroxychloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CCO)CC)=CC=NC2=C1 XXSMGPRMXLTPCZ-UHFFFAOYSA-N 0.000 description 1
- 230000006028 immune-suppresssive effect Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 229940073062 imuran Drugs 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 201000010849 intracranial embolism Diseases 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 description 1
- 229960000681 leflunomide Drugs 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000008816 organ damage Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 229960001639 penicillamine Drugs 0.000 description 1
- 208000011906 peptic ulcer disease Diseases 0.000 description 1
- 238000009527 percussion Methods 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 229940030966 pyrrole Drugs 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 150000003873 salicylate salts Chemical class 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000000273 spinal nerve root Anatomy 0.000 description 1
- 235000015096 spirit Nutrition 0.000 description 1
- 201000005671 spondyloarthropathy Diseases 0.000 description 1
- NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 description 1
- 229960001940 sulfasalazine Drugs 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了治疗风湿、腰椎间盘突出的药物及其方法,它是以下述重量配比的原料制成黑蚂蚁30‑60份、土元25‑35份、岩马桑50‑70份、骨碎补50‑70份、苕叶细幸8‑12份、伸筋草25‑35份、路路通25‑35份、透骨草25‑35份、地龙25‑35份。本方由大量通经活络,祛风除湿,活血化瘀,消肿止痛为根本大法。辅以玉米酒助药力直达病所,共奏奇效。本方临床验证十余年,诊治五千余例患者,无任何毒副反应。
Description
技术领域
本发明涉及一种治疗风湿、腰椎间盘突出的药物及其方法,属于中草药技术领域。
背景技术
风湿性疾病是一类侵犯多种组织多系统和内脏器官的自身免疫性疾病。程度不同的免疫性炎症反应,可致成各种组织和器官损伤,严重影响其正常功能,甚至造成致命性损害。现有治疗风湿性疾病的药物可分为如下几类:
1. 非甾类抗炎药(NSAIDs):此类药物的作用,主要为解热,消炎和镇痛,而达到减轻炎症反应和目的。最早为阿司匹林(乙酰水杨酸)至今仍为治疗急性风湿热及风湿性关节炎的有效药物。后来生产出各种水杨酸类药物,常用的有布洛芬,双氯芬酸,吲哚美辛,吡罗昔康,萘普生等,但各种药物的药代动力学及不良反应各不相同,主要对胃肠,肾,肝和血液系统,使用时一定要注意剂量,用法,副作用等。
2. 肾上腺皮质激素:主要是指糖皮质激素,因为这类药物有抗炎和免疫抑制作用,有较强和快速的消除炎症及炎症反应带来的各种症状,如发热,关节肿胀和疼痛。所以对各种风湿性疾病,常被用为第一线药物。临床上应用的有短效,中效和长效等制剂。用法有口服,肌肉或关节腔内注射,静脉注射,可根据病种,病情作不同的选择。但由于其并非根治药物,长期大量使用可诱发感染,骨质疏松,股骨头坏死,糖尿病,消化性溃疡,高血压,精神异常等;且如停药过快易产生病情反跳现象,故应注意根据病种和病情,调节使用药物的种类和剂量。除重症患者外,原则上以小剂量,短疗程为宜。
3. 改善病情的抗风湿药物(DMARDs)又称为慢作用抗风湿药物。此类药物包括许多种类结构不同,作用各异的药物。它们的共性是起效比较慢,有一定蓄积作用,故停药后,作用消失也较慢,仍可维持一段时间。它们并无直接消炎止痛作用,但通过不同的机制可以起到抗炎及免疫或免疫抑制作用。因而,也可以改善关节肿胀,疼痛,僵直和减轻系统性症状,降低急性期反应蛋白,血沉。如使用时间较长,也可改善其他免疫指标,如RF,ANA等。有的尚可使放射影像得到改善。DMARDs类的药物包括有抗疟药-氯喹、羟氯喹,柳氮磺胺吡啶,甲氨蝶呤,硫唑嘌呤,环磷酰氨,青霉胺,金制剂,环孢素A及来氟米特。
以上各种药物对人体重要的脏器(肝,肾,膀胱,肺,胃肠,生殖腺)和组织(骨髓)各有不同的毒性作用,使用效果并不是很好;
腰椎间盘突出症是较为常见的疾患之一,主要是因为腰椎间盘各部分(髓核、纤维环及软骨板),尤其是髓核,有不同程度的退行性改变后,在外力因素的作用下,椎间盘的纤维环破裂,髓核组织从破裂之处突出(或脱出)于后方或椎管内,导致相邻脊神经根遭受刺激或压迫,从而产生腰部疼痛,一侧下肢或双下肢麻木、疼痛等一系列临床症状;现有的治疗分为手术治疗与非手术治疗,.非手术疗法主要针对症状较轻的患者,且治愈缓慢,现有的显微椎间盘摘除、显微内镜下椎间盘摘除、经皮椎间孔镜下椎间盘摘除等微创外科技术使手术损伤减小,取得了良好的效果,但其费用较高,且易复发。
而对脑血栓偏瘫后遗症目前尚无很好的治疗手段,现多采用康复性治疗,效果较慢。
发明内容
本发明要解决的技术问题是:提供一种对风湿、内风湿、跌打损伤、颈椎、腰椎间盘突出症、下肢静脉曲张、脑血栓偏瘫治疗有明显效果的治疗风湿、颈、腰椎间盘突出及脑血栓偏瘫后遗症的药物及方法,可以克服现有技术的不足
本发明的技术方案是:治疗风湿、颈、腰椎间盘突出及脑血栓偏瘫后遗症的药物,它由下述重量配比的原材料构成:黑蚂蚁30g-60份、土元25-35份、岩马桑50-70份、骨碎补50-70份、苕叶细辛8-12份、伸筋草25-35份、路路通25-35份、透骨草25-35份、地龙25-35份。
治疗风湿、颈、腰椎间盘突出及脑血栓偏瘫后遗症的药物,它由下述重量配比的原材料构成:
黑蚂蚁30-60份、土元30份、岩马桑60份、追风伞30份、见血飞30份、刺五加30份、威灵仙30份、骨碎补60份、苕叶细辛10份、对叶四块瓦30份、虎杖30份、红禾麻30份、红牛克膝30份、八爪金龙30份、岩川芎40份、野葡萄根30份、五花血藤60份、伸筋草30份、通草30份、路路通30份、排风藤30份、香樟根30份、透骨草30份、穿山龙30份、三角枫30份、银花藤30份、茴香根30份、阎王刺10份、野木瓜60份、大风藤15份、甘草15份、地龙30份。
制备治疗风湿、脊柱突出及静脉曲张及脑血栓偏瘫后遗症药物的生产方法,其特征在于:该方法是将上述两种配方规定的重量份的原材料投入装有20kg玉米酒的酒坛中,并对酒坛进行密封,保存半月后即可服用;每次服用量3-5钱,每日二至三次,早、中、晚服用或早晚服用。
与现有技术比较,黔地出异草,夜郎多灵药。本方所用三十二味中草药均出自于贵州山区,以黑蚂蚁为君,滋补肾阴肾阳,鼓舞元气。土元、岩马桑、追风伞、见血飞、刺五加、威灵仙、骨碎补、苕叶细辛、对叶四块瓦、虎杖、红禾麻、红牛克膝、八爪金龙、岩川芎、野葡萄根、五花血藤、伸筋草、通草、路路通、排风藤、香樟根、透骨草、穿山龙、三角枫、银花藤、茴香根、阎王刺、野木瓜、大风藤、甘草、地龙等三十一味大剂量通经活络之品为辅药,意在“治风先治血,血行风自灭”。贵州乃全国风湿病患病率之首,因为独特的气候让生活在这里的人民极易患上该病,我的祖辈长期与疾病作斗争的过程之中,逐步完善和积累了治疗风湿的宝贵经验,救治了很多患者,在当地享有盛名,该方流传在我辈之后,临床验证颈、腰椎间盘突出,静脉曲张,脑血栓后遗症,强直性脊柱炎同样取得很好的疗效。
本方由大量通经活络,祛风除湿,活血化瘀,消肿止痛为根本大法。辅以玉米酒助药力直达病所,共奏奇效。本方临床验证十余年,诊治五千余例患者,无任何毒副反应。
为验证本配方的效果,申请人对留有联系方式的部分患者制作了登记,具体内容如下:
1.杜某某:男、16岁、学生、遵义市绥阳县旺草镇人。该患者因长期上网原因导致腰椎3、4、5突出,压迫右下肢神经。该患者多方治疗未愈,于2008年6月经人介绍来我处治疗,本所用自制的“玄驹透骨液”治疗月余,疗效突出,随访至今未见复发。
2.廖某某:男、52岁、遵义市团溪镇人。2008年在XX镇宏强米厂上班时扭伤腰部放射性疼痛月余,经多方治疗无效来我处求诊,遵义市人民医院CT显示该患者T5-S1椎间盘突出,压迫硬膜囊,本所投以自制“玄驹透骨液”治疗三月,效果肯定,随访至今未复发。
3.张某某:女、80岁、重庆人、XX企业董事长夫人。患腰椎间盘突出二十余年,经多方治疗反复发作,逢气候变化尤为严重,经本厂在我处治愈职工介绍来我处诊治,CT显示颈椎生理曲度变直,退行性改变T2-3-4突出,腰椎T4-5突出,压迫硬膜囊,触及双侧神经根,投以本处自制“玄驹透骨液”治疗半年,效果显著。(注:该患者同时患有高血压、糖尿病,告知服药期间用白开水适量降低酒液浓度服用,未见不良反应。)随访至今未见复发。
4.张某:男、60岁、务川县黄都镇人、农民。该患者患有颈椎、腰椎突出五年,主症:头痛、手指麻木、腰部牵扯下肢疼痛,基本丧失劳动能力。经人介绍来我处诊治,投以“玄驹透骨液”治疗半年康复,(患者因患颈腰疾病五年未曾上街赶集,康复后特此致电表达谢意)至今患者愈后良好,未见复发。
5.彭某某:男、55岁、XX检察院干部。于2009年和朋友打篮球时不慎手指触及篮球损伤,多方求诊年余,食指关节红肿疼痛,功能障碍,本所用自制的“玄驹透骨液”外敷内服一月治愈,随访至今未复发。
6.曾某某:女、25岁、正安县土平镇人、农民。2012年因肘关节红肿热痛原因求诊于遵义XX医院,该院诊断为“内风湿”,诊治月余,疗效不满意出院,经人介绍来我处诊治,我所投以“玄驹透骨液”治疗三月,效果肯定,嘱其尽量少进食嘌呤碱类食品,减少复发率,随访至今未见复发。
7.司马某某:男、45岁、珠海人、XX企业老总。患颈椎病八年,头痛、恶心、呕吐伴右侧肢体麻木,本厂职工用我所自制的“玄驹透骨液”药酒送其试用一月,症状有所改善,乘飞机专程来我所求药,本所投以“玄驹透骨液”治疗半年,已愈,随访至今未见复发。
8.王某:女、48岁、XX医院妇产科主任。身患腰椎疾病十年,多方治疗无效,经人介绍来我所诊治,CT显示T2-3-4-5突出,压迫硬膜囊及神经,我所投以自制“玄驹透骨液”治疗四月康复,随访至今未见复发,疗效肯定。
9.罗某:男、48岁、遵义市南北县人。因患下肢静脉曲张两年,多方求治无效,经XX医院行静脉术半年后复发,后经人介绍来我处诊治,本所予以九针磁圆梅针扣刺局部五次,投以自制“玄驹透骨液”治疗月余康复,送以锦旗“良药济世,药到病除”,随访至今未曾复发。
10.邱某:男、65岁、遵义市红花岗区人,农业银行职工。于2012年因突发脑血栓,求治于XX人民医院,治疗月余,患者右侧肢体功能丧失,生活不能自理,出院后来我所救治,本所辅以针灸和“玄驹透骨液”治疗月余,患者右上下肢功能明显改善,生活能够自理,继续服用“玄驹透骨液”半年,疗效尤为显著,随访至今,愈后良好。
以上只为申请人罗列出的部分患者,其代表了本申请在治疗颈椎、腰椎、风湿、内风湿、静脉曲张、脑血栓等疾病方面疗效确切,愈后良好,临床验证五千余例,未见不良反应和毒副作用;且治愈周期短,不会复发,具有非常好的市场前景,和推广价值。
具体实施方式
实施例1:取黑蚂蚁30g份、土元25g、岩马桑50g、骨碎补50g、苕叶细辛8g、伸筋草25g、路路通25g、透骨草25g和地龙25g,投入装有20kg玉米酒的酒坛中,并对酒坛进行密封,保存半月后即可服用;每次服用量3-5钱,每日二次。
实施例2:取黑蚂蚁60g、土元35g、岩马桑70g、骨碎补70g、苕叶细辛12g、伸筋草35g、路路通35g、透骨草35g和地龙35g投入装有20kg玉米酒的酒坛中,并对酒坛进行密封,保存半月后即可服用;每次服用量3-5钱,每日二次。
实施例3:取黑蚂蚁45g、土元30g、岩马桑60g、骨碎补60g、苕叶细辛10g、伸筋草30g、路路通30g、透骨草30g和地龙30g投入装有20kg玉米酒的酒坛中,并对酒坛进行密封,保存半月后即可服用;每次服用量3-5钱,每日二次。
实施例4:黑蚂蚁30-60g、土元30g、岩马桑60g、追风伞30g、见血飞30g、刺五加30g、威灵仙30g、骨碎补60g、苕叶细辛10g、对叶四块瓦30g、虎杖30g、红禾麻30g、红牛克膝30g、八爪金龙30g、岩川芎40g、野葡萄根30g、五花血藤60g、伸筋草30g、通草30g、路路通30g、排风藤30g、香樟根30g、透骨草30g、穿山龙30g、三角枫30g、银花藤30g、茴香根30g、阎王刺10g、野木瓜60g、大风藤15g、甘草15g和地龙30g投入装有20kg玉米酒的酒坛中,并对酒坛进行密封,保存半月后即可服用;每次服用量3-5钱,每日二次。
Claims (2)
1.一种治疗风湿、腰椎间盘突出的药物,其特征在于:它由下述重量配比的原材料构成:
黑蚂蚁30-60份、土元30份、岩马桑60份、追风伞30份、见血飞30份、刺五加30份、威灵仙30份、骨碎补60份、苕叶细幸10份、对叶四块瓦30份、虎杖30份、红禾麻30份、红牛克膝30份、八爪金龙30份、岩川芎40份、野葡萄根30份、五花血藤60份、伸筋草30份、通草30份、路路通30份、排风藤30份、香樟根30份、透骨草30份、穿山龙30份、三角枫30份、银花藤30份、茴香根30份、阎王刺10份、野木瓜60份、大风藤15份、甘草15份、地龙30份。
2.根据权利要求1所述的治疗风湿、腰椎间盘突出的药物的生产方法,其特征在于:该方法是将规定重量份的原材料投入装有20倍原材料重量份的玉米酒的酒坛中,并对酒坛进行密封,保存半月后即可服用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410246427.XA CN104083428B (zh) | 2014-06-05 | 2014-06-05 | 治疗风湿、腰椎间盘突出的药物及其方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410246427.XA CN104083428B (zh) | 2014-06-05 | 2014-06-05 | 治疗风湿、腰椎间盘突出的药物及其方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104083428A CN104083428A (zh) | 2014-10-08 |
CN104083428B true CN104083428B (zh) | 2018-02-27 |
Family
ID=51631256
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410246427.XA Expired - Fee Related CN104083428B (zh) | 2014-06-05 | 2014-06-05 | 治疗风湿、腰椎间盘突出的药物及其方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104083428B (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108853412A (zh) * | 2018-07-24 | 2018-11-23 | 天柱县国荣盲人按摩有限公司 | 一种治疗颈椎、腰椎病的喷雾剂制备方法及其应用 |
CN112843161A (zh) * | 2021-03-01 | 2021-05-28 | 杨光林 | 一种治疗椎间盘疾病及骨质增生的外用中药及其制备方法 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103055091A (zh) * | 2012-12-21 | 2013-04-24 | 苗庆芬 | 疗骨消痛膏 |
-
2014
- 2014-06-05 CN CN201410246427.XA patent/CN104083428B/zh not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CN104083428A (zh) | 2014-10-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101664480B (zh) | 一种治疗骨质增生症的中草药剂 | |
CN104083428B (zh) | 治疗风湿、腰椎间盘突出的药物及其方法 | |
CN106511510A (zh) | 用于治疗风寒湿痹筋骨劳损的药物组合物 | |
CN103990057A (zh) | 一种治疗风湿骨病的药物及其制备方法 | |
CN103520633A (zh) | 抗癌活血消痞膏的加工方法 | |
CN114375196A (zh) | 一种治疗骨性关节炎的中药组合物 | |
CN102343008A (zh) | 一种治疗腰椎间盘突出症的中药组合物 | |
CN102240351B (zh) | 一种治疗关节炎骨质增生椎间盘突出颈椎病的中药药物 | |
CN108939058A (zh) | 一种活血止痛的中药制剂及制备方法 | |
CN103690673A (zh) | 一种治疗风湿的配方胶囊 | |
CN106511905A (zh) | 一种用于治疗颈椎病的中药制剂及其制备方法 | |
CN101530522B (zh) | 治疗风寒湿痛的中药制剂 | |
CN106806399A (zh) | 金骨莲片中药饮片组合制剂、制备方法及组合包装 | |
CN105343221A (zh) | 一种治疗腰腿痛的中药组合物 | |
CN104547088A (zh) | 一种治疗椎间盘突出症、骨关节炎的药物及其制备方法 | |
CN104606313A (zh) | 治疗骨关节疾病和骨伤的中药膏剂及制备方法 | |
CN104069299B (zh) | 一种治疗骨折术后关节功能性障碍的中药组合物及其制备方法 | |
CN103285100A (zh) | 一种治疗转移性癌性骨痛的外用中药组合物 | |
CN108420856A (zh) | 治疗骨关节、筋络疼痛的中药制剂 | |
CN104606396B (zh) | 一种治疗骨骺骨软骨炎的药物及其制备方法 | |
CN101361882B (zh) | 治疗风湿骨病的中药制剂 | |
CN102614350A (zh) | 一种治疗颈椎病的中药 | |
CN109260307B (zh) | 一种具有促排石作用的中药组合物及其制备方法 | |
CN103990016B (zh) | 治疗风湿骨病的中药组合物及其制剂和制备方法 | |
CN104771701A (zh) | 一种治疗腰颈椎病的中药组合物、散剂及制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20180227 |